Call for Appointment Accepts New Patients
I have been treating patients with cancer and doing preclinical and clinical research for over 30 years, with experience in several countries, cultures and medical systems. I mainly treat patients with thoracic malignancies, and, in particular, patients with lung cancer, thymic tumors and mesothelioma. Providing the best care possible has always been my goal in my career, and this has meant a deep involvement in research.
Giuseppe Giaccone, MD, PhD, is an internationally recognized expert in the field of lung cancer and developmental therapeutics. In September 2019, he joined Weill Cornell Medicine and NewYork-Presbyterian Hospital as Chief of Thoracic Oncology and Associate Director for Clinical Research at the Sandra and Edward Meyer Cancer Center. He also directs the phase I clinical trial program for early drug development.
Dr. Giaccone received his MD cum laude from the University of Torino Medical School in 1980, followed by training in clinical oncology and internal medicine, which he completed at the University of Torino in 1988. He spent the next two years in the National Cancer Institute’s (NCI) Medical Oncology Branch under the direction of Dr. John Minna. Following his training at the NCI, Dr. Giaccone received his PhD from the Vrije University Medical Center in Amsterdam, The Netherlands. He served as a senior medical oncologist at the Medical Center from 1990 to 2000, when he was appointed Professor of Medical Oncology. He became Head of the Center's Department of Medical Oncology in 2003.
Dr. Giaccone played an influential role at the European Organization for Research and Treatment of Cancer (EORTC), serving as a member of the EORTC's Lung Cancer Cooperative Group since 1982 and as its Chair from 1993 to 2000. He also led several major clinical studies focusing on lung cancer and other thoracic tumors.
Dr. Giaccone was appointed Chief of the Medical Oncology Branch of the Center for Cancer Research of the National Cancer Institute in April 2007 where he was in charge of restructuring the clinical intramural program. In January 2013, Dr. Giaccone joined the Lombardi Comprehensive Cancer Center at Georgetown University in Washington, DC as the Associate Director for Clinical Research and the Director of Clinical Research for the MedStar Health Cancer Network’s Washington Region, and Professor of Medical Oncology and Pharmacology.
Dr. Giaccone’s research activity is mainly focused on the study of the biology of lung cancer and thymic tumors, and treatment of these tumor types. He has made seminal discoveries that have disclosed new ways to treat lung cancer and to diagnose thymic tumors. Dr. Giaccone has published more than 500 peer-reviewed papers and contributed to more than 30 book chapters.
Dr. Loehrer is director of the Indiana University Melvin and Bren Simon Cancer Center, an IU Distinguished Professor, H.H. Gregg Professor of Oncology and associate dean for cancer research at the Indiana University School of Medicine.
Recognized as a prolific clinical researcher, Dr. Loehrer is a specialist in a variety of cancers, including cancers of the testis, bladder, colon, pancreas and, most notably, the thymus gland. His work has led to the approval of ifosfamide for the treatment of testicular cancer, and he helped develop therapies for the treatment of several malignancies, including thymoma and cancer of the bladder, colon and pancreas.
His research related to thymic cancer has been recognized with the Exceptional Service Award of the Foundation for Thymic Research. He is a founder of the Hoosier Cancer Research Network (formerly known as the Hoosier Oncology Group) and served as its chairman for two decades. He has also served as chairman of the Genitourinary Committee for the Eastern Cooperative Oncology Group (ECOG) and served as the director of the gastrointestinal research program at the IU Simon Cancer Center.
Dr. Loehrer has received numerous awards, including the Flick Family Fund Award, the American Cancer Society Fellowship, the American Cancer Society Junior Faculty Award, the Glenn Irwin Experience Excellence Award, the ECOG Young Investigator Award, the Danielson Award, the Collaborator of the Year Award from the Walther Cancer Institute, and the W. George Pinnell Award. In 2010, he received the Special Recognition Award from the American Society of Clinical Oncology (ASCO).
Dr. Loehrer has served on the boards of the ECOG Foundation, the American Society of Clinical Oncology and the American Board of Internal Medicine. He was editor-in-chief of the Yearbook of Oncology and co-editor of the Yearbook of Medicine and has served on the editorial boards of numerous journals. He served as the chair of the newly formed Leadership Development Program of ASCO.
Dr. Loehrer received his undergraduate degree in mechanical engineering from Purdue University in 1975 and his medical degree from Rush Medical College in 1978. He completed his internship and residency at Rush Presbyterian St. Luke’s Medical Center and a fellowship in medical oncology at Indiana University. In 1983, he joined the faculty of the IU School of Medicine.
Dr. Rajan received his M.B.B.S. and M.D. degrees from the University of Delhi, New Delhi, India, in 1998 and 2002, respectively. He then joined the State University of New York in Syracuse, where he completed his internal medicine residency training in 2005, followed by fellowship training in hematology and medical oncology, which he completed in 2008. In July 2008, Dr. Rajan joined the Thoracic Oncology Section of the Medical Oncology Branch. His work focuses on developing new therapies for patients with lung cancer and thymic malignancies. Dr. Rajan also serves as the course coordinator for the clinical elective program in medical oncology and organizes the bi-monthly multidisciplinary thoracic oncology tumor board meeting.
Aaron S. Mansfield, M.D., is a translational scientist with a focus on early-phase clinical trials, especially for lung cancer and mesothelioma. Dr. Mansfield's research is focused on understanding how tumors avoid destruction by the immune system.
Dr. Mansfield hopes to introduce novel treatments and tools to treat lung cancer, mesothelioma and their associated complications.